Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DURECT Corporation (DRRX) SEC filings page on Stock Titan provides access to historical regulatory documents filed by this former Nasdaq-listed biopharmaceutical company. These filings trace DURECT’s evolution as a late-stage developer of epigenetic therapies, its financial reporting as a public issuer, and the steps that led to its acquisition by a subsidiary of Bausch Health Americas, Inc. and subsequent delisting.
For users analyzing DURECT’s business, earlier periodic reports and current reports on Form 8-K describe the company’s focus on larsucosterol, an investigational epigenetic modulator in clinical development for alcohol-associated hepatitis (AH), and disclose that the U.S. Food and Drug Administration granted larsucosterol Fast Track and Breakthrough Therapy designations for this indication. Other filings reference the company’s FDA-approved non-opioid analgesic POSIMIR, based on its SABER platform technology, and the sale of the ALZET osmotic pump product line.
Later filings are particularly important for understanding DRRX’s trading and registration status. A series of Forms 8-K in 2025 describe the Agreement and Plan of Merger with Bausch Health Americas, Inc., the commencement and terms of the tender offer for all outstanding DURECT shares, amendments to the merger agreement, and the completion of the merger on September 11, 2025. A Form 25 filed by The Nasdaq Stock Market LLC on that date documents the removal of DURECT’s common stock from listing on Nasdaq. Subsequently, a Form 15 filed on September 22, 2025 certifies the termination of registration of the common stock under Section 12(g) of the Exchange Act and the suspension of DURECT’s duty to file reports under Sections 13 and 15(d).
On Stock Titan, these filings are accompanied by AI-generated highlights that help explain key sections, such as change-of-control terms in merger-related 8-Ks, delisting notices, and the implications of Form 15 deregistration. Users can quickly identify documents related to corporate transactions, historical financial condition, and the regulatory history of larsucosterol and POSIMIR, while still having direct access to the full text as filed with the SEC.
Durect Corporation filed an S-8 registration statement listing numerous prior S-8 filings and registrations of common stock for employee plans spanning 2000 through 2024. The filing enumerates specific share amounts reserved under various plans (including Employee Stock Purchase Plans, Stock Plans, Directors' Stock Option Plan and legacy plans) and notes a 1-for-10 reverse stock split effected December 5, 2022, with several later registrations stated as ‘‘after giving effect’’ to that split.
Durect Corporation filed an S-8 post-effective amendment that lists prior registration statements and the number of common shares registered for various employee plans dating from 2000 through November 14, 2024. The filing documents multiple past registrations under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan and the 2000 Stock Plan (and related director/legacy plans), and notes a 1-for-10 reverse stock split effected December 5, 2022. The document also identifies the company as incorporated in Delaware and includes an EIN and signature by the CFO, Timothy M. Papp.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing prior S-8 registration statements and the number of shares reserved under various employee equity plans over time. The filing documents multiple historical registrations dating from October 5, 2000 through November 14, 2024, including registrations under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan, the 2000 Stock Plan and director/legacy plans. The filing also notes a 1-for-10 reverse stock split effective December 5, 2022.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing prior S-8 registration statements and the amounts of common stock registered under various employee plans over time. The filing documents multiple historical registrations (ranging from tens of thousands to millions of shares) for stock option plans and employee stock purchase plans, notes a 1-for-10 reverse stock split effective December 5, 2022, and is signed by the CFO.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
